BioOrbit, the startup developing hardware for a future pharmaceuticals factory in space, has landed $13.2M in seed funding. The capital infusion will accelerate its work on large-scale protein drug crystallization, with an in-orbit demonstration targeted for early 2025.
The company's grand aim is to establish a full-fledged pharmaceuticals factory in space within the next decade, a bold vision that has now secured significant capital. This seed round will help BioOrbit push towards its ambitious timeline, building on its participation in programs like the Airbus Accelerator and Seraphim Space Accelerator.
